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Abstract: Nanoparticle (NP) drug delivery systems (5-250 nm) have the potential to improve
current disease therapies because of their ability to overcome multiple biological barriers and
releasing a therapeutic load in the optimal dosage range. Rapid clearance of circulating
nanoparticles during systemic delivery is a critical issue for these systems and has made it
necessary to understand the factors affecting particle biodistribution and blood circulation half-
life. In this review, we discuss the factors which can inﬂuence nanoparticle blood residence
time and organ speciﬁc accumulation. These factors include interactions with biological barriers
and tunable nanoparticle parameters, such as composition, size, core properties, surface
modiﬁcations (pegylation and surface charge), and ﬁnally, targeting ligand functionalization. All
these factors have been shown to substantially affect the biodistribution and blood circulation
half-life of circulating nanoparticles by reducing the level of nonspeciﬁc uptake, delaying
opsonization, and increasing the extent of tissue speciﬁc accumulation.
Keywords: Biodistribution; circulation half-life; polymeric nanoparticles
Introduction
Nanoparticles have drawn increasing interest from every
branch of medicine
1–5 for their ability to deliver drugs in
the optimum dosage range, often resulting in increased
therapeutic efﬁcacy of the drug, weakened side effects,
6,7
and improved patient compliance. Today, there are several
examples of nontargeted NPs currently used in clinical
practice (Doxil
8–11 and Daunoxome
12) and in clinical de-
velopment (Cyclosert).
13 Early success of these lipid-based
vesicular drug delivery nanoparticles has led to the investiga-
tion and development of many different compositions of
polymeric nanoparticles, including polymeric micelles, den-
drimers, drug conjugates, and polypeptide- and polysaccha-
ride-based nanoparticles. Among these, Genexol-PM [meth-
oxy-PEG-poly(D,L-lactide)Taxol] is the ﬁrst polymeric micellar
nanoparticle in phase II clinical trials in the United States.
14,15
Generally, clinical success correlates well with pharmaco-
logical and toxicological parameters. Blood circulation
residence, maximal tolerated dose (MTD), and selectivity
are the most important factors for achieving a high thera-
peutical index and corresponding clinical success. Polymeric
nanoparticles are deﬁned by their morphology and polymer
composition in the core and corona (Figure 1). The thera-
peutic load is typically conjugated to the surface of the
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Published on Web 08/04/2008nanoparticle, or encapsulated and protected inside the core.
The delivery systems can be designed to provide either
controlled release or a triggered release of the therapeutic
molecule.
16,17 The nanoparticle surface can then be func-
tionalized by various methods to form the corona. Surface
functionalization can be utilized to increase residence time
in the blood, reduce nonspeciﬁc distribution, and, in some
cases, target tissues or speciﬁc cell surface antigens with a
targeting ligand (peptide, aptamer, antibody/antibody frag-
ment, small molecule). For instance, it is well established
that hydrophilic polymers, most notably poly(ethylene glycol)
(PEG), can be grafted, conjugated, or absorbed to the surface
of nanoparticles to form the corona, which provides steric
stabilization and confers “stealth” properties such as preven-
tion of protein absorption.
18,19 Surface functionalization can
address the major limiting factor for long-circulating nano-
particle systems, which is protein absorption. Proteins
adsorbed on the surface of the nanoparticle promote op-
sonization, leading to aggregation and rapid clearance from
the bloodstream.
20–23 The resultant rapid clearance is due
to phagocytosis by the mononuclear phagocyte system (MPS)
in the liver and splenic ﬁltration. Typically, the majority of
opsonized particles are cleared by a receptor-mediated
mechanism in fewer than a few minutes due to the high
concentration of phagocytic cells in the liver and spleen, or
they are excreted.
21 Thus, over the past 20 years, numerous
approaches to improving nanoparticle blood residence and
accumulation in speciﬁc tissues for the treatment of disease
have been developed. In this review, we will discuss the
effects of physiological tissue defects (high permeability) and
polymeric nanoparticle physicochemical properties on their
biodistribution and clearance. Speciﬁcally, polymeric com-
position, nanoparticle size, pegylation, surface charge, and
targeting functionality will be discussed.
Overcoming Biological Barriers: Effect of
Physiological Defects
Numerous biological barriers exist to protect the human
body from invasion by foreign particles. These barriers
(1) Zhang, L.; et al. Nanoparticles in Medicine: Therapeutic Ap-
plications and Developments. Clin. Pharmacol. Ther. 2008, 83,
761–769.
(2) Moghimi, S. M.; Hunter, A. C. Poloxamers and poloxamines in
nanoparticle engineering and experimental medicine. Trends in
biotechnology 2000, 18, 412–420.
(3) Farokhzad, O. C.; Langer, R. Nanomedicine: Developing smarter
therapeutic and diagnostic modalities. AdV. Drug DeliVery ReV.
2006, 58, 1456–1459.
(4) Shaffer, C. Nanomedicine transforms drug delivery. Drug
DiscoVery Today 2005, 10, 1581–1582.
(5) Alexis, F.; et al. New frontiers in nanotechnology for cancer
treatment. Urol. Oncol. 2008, 26, 74–85.
(6) Safra, T.; et al. Pegylated liposomal doxorubicin (doxil): Reduced
clinical cardiotoxicity in patients reaching or exceeding cumula-
tive doses of 500 mg/m
2. Ann. Oncol. 2000, 11, 1029–1033.
(7) Fassas, A.; Buffels, R.; Kaloyannidis, P.; Anagnostopoulos, A.
Safety of high-dose liposomal daunorubicin (daunoxome) for
refractory or relapsed acute myeloblastic leukaemia. Br. Jo.
Haematol. 2003, 122, 161–163.
(8) James, N. D.; et al. Liposomal doxorubicin (Doxil): An effective
new treatment for Kaposi’s sarcoma in AIDS. Clin. Oncol. 1994,
6, 294–296.
(9) Doxil receives FDA market clearance. AIDS Patient Care and
STDs, 1996; Vol. 10, p 135.
(10) Muggia, F. M. Doxil in breast cancer. J. Clin. Oncol. 1998, 16,
811–812.
(11) Food and Drug Administration. FDA approves DaunoXome as
ﬁrst-line therapy for Kaposi’s sarcoma. Journal of the Interna-
tional Association of Physicians in AIDS Care 1996, 2, 50–51.
(12) DaunoXome approved. AIDS Patient Care and STDs, 1996; Vol.
10, p 263.
(13) Schluep, T.; et al. Preclinical efﬁcacy of the camptothecin-
polymer conjugate IT-101 in multiple cancer models. Clin.
Cancer Res. 2006, 12, 1606–1614.
(14) Kim, D. W.; et al. Multicenter phase II trial of Genexol-PM, a
novel Cremophor-free, polymeric micelle formulation of pacli-
taxel, with cisplatin in patients with advanced non-small-cell lung
cancer. Ann. Oncol. 2007, 18, 2009–2014.
(15) Lee, K. S.; et al. Multicenter phase II trial of Genexol-PM, a
Cremophor-free, polymeric micelle formulation of paclitaxel, in
patients with metastatic breast cancer. Breast Cancer Res. Treat.
2008, 108, 241–250.
(16) Pridgen, E. M.; Langer, R.; Farokhzad, O. C. Biodegradable,
polymeric nanoparticle delivery systems for cancer therapy.
Nanomedicine (London, U.K.) 2007, 2, 669–680.
(17) Moghimi, S. M. Recent developments in polymeric nanoparticle
engineering and their applications in experimental and clinical
oncology. Anti-Cancer Agents Med. Chem. 2006, 6, 553–561.
(18) Avgoustakis, K. Pegylated poly(lactide) and poly(lactide-co-
glycolide) nanoparticles: Preparation, properties and possible
applications in drug delivery. Curr. Drug DeliVery 2004, 1, 321–
333.
(19) Otsuka, H.; Nagasaki, Y.; Kataoka, K. PEGylated nanoparticles
for biological and pharmaceutical applications. AdV. Drug
DeliVery ReV. 2003, 55, 403–419.
(20) Romberg, B.; Hennink, W. E.; Storm, G. Sheddable coatings
for long-circulating nanoparticles. Pharm. Res. 2008, 25, 55–
71.
Figure 1. Nanoparticle platforms for drug delivery.
Polymeric nanoparticle platforms are characterized
by their physicochemical structures, including poly-
merosome, solid polymeric nanoparticle, nanoshell,
dendrimer, polymeric micelle, and polymer-drug
conjugates.
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506 MOLECULAR PHARMACEUTICS VOL. 5, NO. 4include cellular and humoral arms of the immune system as
well as mucosal barriers among others. These barriers must
be overcome in order for nanoparticles to reach their target
(Figure 2). Due to their unique size, and amenability to
surface functionalization to incorporate the desired charac-
teristics, nanoparticles are particularly well suited to over-
coming these barriers. This is especially true in the case of
abnormal neovascularization. Blood vessels are responsible
for delivering molecules, nutrients, and oxygen to organs
throughout the body. Endothelia composing the blood vessels
have been classiﬁed as continuous, fenestrated, or discon-
tinuous, depending on the morphological features of the
endothelium. The continuous endothelium morphology ap-
pears in arteries, vessels,
24,25 and the lungs.
26 In contrast,
fenestrated endothelium
27 appears in glands,
28 digestive
mucosa, and kidney. Fenestrae have an octagonal symmetry
with radial ﬁbrils interweaving in a central point forming
pores of approximately 60 nm. Discontinuous endothelium
is a characteristic of the liver (fenestrea of 50-100 nm)
29
and bone marrow. Endothelial cells from the blood vessels
are able to respond to the physiological environment,
resulting in angiogenic activity. Angiogenesis
30,31 is well-
characterized for cancers
32 as well as ocular and inﬂamma-
tory diseases,
33 with antiangiogenesis compounds commonly
used for therapy.
34,35 Angiogenesis during tumor growth
results in defective hypervasculature and a deﬁcient lym-
phatic drainage system, which has given rise to the concept
of passive targeting of nanoparticles to tumors through the
“enhanced permeability and retention” (EPR) effect.
36,37 The
EPR is a unique feature which allows macromolecules or
drug delivery nanoparticles (cutoff size of >400 nm) to
preferentially accumulate and diffuse in tumor tissues.
38
Long-circulating drug delivery nanoparticles are able to
extravasate into tumor tissues, accumulate, and release the
therapeutic drug locally in the extracellular area. Similarly,
abnormal neovascularization or angiogenesis as well as
enhanced vascular permeability are major causes of many
ocular disorders, including age-related macular degeneration
(AMD), retinopathy of prematurity (ROP), ischemic retinal
vein occlusions, and diabetic retinopathy (DR), causing
irreversible vision loss. In ocular disorders, the angiogenic
process appears to be due to a stimulus response for retinal
neovascularization. The stimulus can be tissue hypoxia,
inﬂammatory cell inﬁltration, increased local concentration
of cytokines (VEGF, PDGF, FGF5 TNF, IGF etc.). The result
(21) Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Long-circulating
and target-speciﬁc nanoparticles: Theory to practice. Pharmacol.
ReV. 2001, 53, 283–318.
(22) Vittaz, M.; et al. Effect of PEO surface density on long-
circulating PLA-PEO nanoparticles which are very low comple-
ment activators. Biomaterials 1996, 17, 1575–1581.
(23) Owens, D. E., III; Peppas, N. A. Opsonization, biodistribution,
and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm.
2006, 307, 93–102.
(24) Predescu, D.; Palade, G. E. Plasmalemmal vesicles represent the
large pore system of continuous microvascular endothelium.
Am. J. Physiol. 1993, 265, H725–H733.
(25) Simionescu, M.; Simionescu, N.; Palade, G. E. Morphometric
data on the endothelium of blood capillaries. J. Cell Biol. 1974,
60, 128–152.
(26) Brigham, K. L. Estimations of permeability properties of
pulmonary capillaries (continuous endothelium). Physiologist
1980, 23, 44–46.
(27) Ludatscher, R. M.; Stehbens, W. E. Vesicles of fenestrated and
non-fenestrated endothelium. Z. Zellforsch. Mikrosk. Anat. 1969,
97, 169–177.
(28) Ryan, U. S.; Ryan, J. W.; Smith, D. S.; Winkler, H. Fenestrated
endothelium of the adrenal gland: Freeze-fracture studies. Tissue
Cell 1975, 7, 181–190.
(29) Braet, F.; et al. Contribution of high-resolution correlative
imaging techniques in the study of the liver sieve in three-
dimensions. Microsc. Res. Tech. 2007, 70, 230–242.
(30) Eisenstein, R. Angiogenesis in arteries: review. Pharmacol. Ther.
1991, 49, 1–19.
(31) Folkman, J. What is the role of endothelial cells in angiogenesis.
Laboratory InVestigation: A Journal of Technical Methods and
Pathology 1984, 51, 601–604.
(32) Folkman, J. Tumor angiogenesis: Therapeutic implications.
N. Engl. J. Med. 1971, 285, 1182–1186.
(33) Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and
other disease. Nat. Med. 1995, 1, 27–31.
(34) Folkman, J.; Ingber, D. Inhibition of angiogenesis. Semin. Cancer
Biol. 1992, 3, 89–96.
(35) Kerbel, R.; Folkman, J. Clinical translation of angiogenesis
inhibitors. Nat. ReV. 2002, 2, 727–739.
(36) Maeda, H. The enhanced permeability and retention (EPR) effect
in tumor vasculature: The key role of tumor-selective macro-
molecular drug targeting. AdV. Enzyme Regul. 2001, 41, 189–
207.
(37) Greish, K. Enhanced permeability and retention of macromo-
lecular drugs in solid tumors: A royal gate for targeted anticancer
nanomedicines. J. Drug Targeting 2007, 15, 457–464.
(38) Hobbs, S. K.; et al. Regulation of transport pathways in tumor
vessels: Role of tumor type and microenvironment. Proc. Natl.
Acad. Sci. U.S.A. 1998, 95, 4607–4612.
Figure 2. Biodistribution and clearance of polymeric
nanoparticles. Tissue defects, stealth properties,
targeting, and the size of the nanoparticles are major
factors affecting the biodistribution and clearance of
polymeric nanoparticles.
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zational structure of the neural retina or break through the
inner limiting membranes into the vitreous.
39 Many other
disorders are also characterized by angiogenesis or vascu-
lature defects such as obesity,
40 asthma,
41 diabetes,
42,43 and
multiple sclerosis.
44,45 The development of new imaging
systems and medical knowledge about physiological defects
is leading to novel therapeutic approaches using nanoparticle
drug delivery systems. It is now well accepted that nano-
particles are suitable for crossing biological barriers through
tissue diffusion, extravasation, and escape from hepatic
ﬁltration.
Nanoparticle Properties
Composition. Historically, the administration of thera-
peutic agents has been limited by multiple factors, primary
among these being low solubility, stability and rapid clear-
ance. The result is a short circulation half-life and low
efﬁcacy, making frequent administration necessary. Ad-
ditionally, there can be signiﬁcant side effects in non-diseased
tissues that adsorb therapeutic agent. These issues have led
to the development of various targeting strategies aimed at
increasing therapeutic index, including monoclonal antibodies
and immunoconjugates. Some of the strategies are currently
used in clinical practice and others are in clinical develop-
ment.
46 In addition to these strategies, it has been shown
that polymer-drug conjugates can substantially improve the
blood residence time and weaken side effects. It is anticipated
that engineered multifunctional nanoparticles can address
issues with targeting as well as carry a more substantial drug
payload. Many polymers have been investigated, including
HPMA [N-(2-hydroxypropyl)methacrylamide], dextran, and
polyglutamate. HPMA and polyglutamate drug conjugates
represent ∼35% of all the polymeric drug delivery systems
in clinical development. The clinical success of AP5346,
PK1, PK2, Xyotax, and CT-2106 seems to be due to their
long circulation half-life, passive targeting ability, and, most
importantly, lower toxicity allowing higher dosages (see
Table 1). Thus far, the main impact of polymer conjugates
has been to improve the pharmacokinetic parameters of drugs
already in clinical use. These polymeric nanocarriers must
be non-toxic, non-immunogenic, and carry sufﬁcient amount
of drug and release the drug at the optimal dose. The use of
poly(ethylene glycol) (PEG) for nanoparticle surface func-
tionalization has had led to very favorable results due to its
intrinsic physicochemical properties but has had limited
impact as a drug conjugate carrier due to low drug loadings.
PEG polymers have low toxicity and no immunogenicity and
are approved by the Food and Drug Administration (FDA)
for clinical use. PEG-drug conjugates or nanoparticles
functionalized with PEG chains have been described as long-
circulating drug delivery systems with potential applications
for systemic drug administration.
21,47 Poly(ethylene glycol)
or poly(ethylene oxide) refers to an oligomer or polymer of
ethylene oxide in linear or branched structures.
48 PEG is a
hydrophilic polymer that can be adsorbed or covalently
attached to the surface of nanoparticles. Hrkach et al. have
demonstrated the formation of PLA-PEG nanoparticles in
a core-corona structure with a solid core and anchored PEG
chains on the surface. Their results showed for the ﬁrst time
that PEG chains, covalently attached to a particle surface,
could exhibit ﬂexibility similar to that of free PEG polymer
dissolved in water. Furthermore, PEG has been shown to
substantially reduce nonspeciﬁc interactions with proteins
through its hydrophilicity and steric repulsion effects, reduc-
ing opsonization and complement activation.
49–55 The chain
length, shape, and density of PEG on the particle surface
have been shown to be the main parameters affecting
nanoparticle surface hydrophilicity and phagocytosis. The
mechanism involved in phagocytosis of opsonized nanopar-
ticles is receptor-mediated by interaction of speciﬁc proteins
absorbed on the surface of the nanoparticles with phagocytes.
(39) Folkman, J. Fundamental concepts of the angiogenic process.
Curr. Mol. Med. 2003, 3, 643–651.
(40) Lijnen, H. R. Angiogenesis and obesity. CardioVasc. Res. 2008,
78, 286–293.
(41) Chetta, A.; Zanini, A.; Torre, O.; Olivieri, D. Vascular remodel-
ling and angiogenesis in asthma: Morphological aspects and
pharmacological modulation. Inﬂammation Allergy Drug Targets
2007, 6, 41–45.
(42) Norrby, K.; Jakobsson, A.; Simonsen, M.; Sorbo, J. Increased
angiogenesis in diabetes. Experientia 1990, 46, 856–860.
(43) Martin, A.; Komada, M. R.; Sane, D. C. Abnormal angiogenesis
in diabetes mellitus. Med. Res. ReV. 2003, 23, 117–145.
(44) Kirk, S.; Frank, J. A.; Karlik, S. Angiogenesis in multiple
sclerosis: Is it good, bad or an epiphenomenon. J. Neurol. Sci.
2004, 217, 125–130.
(45) Siegel, R. C. Angiogenesis in progressive systemic sclerosis.
N. Engl. J. Med. 1972, 286, 217.
(46) Wu, A. M.; Senter, P. D. Arming antibodies: Prospects and
challenges for immunoconjugates. Nat. Biotechnol. 2005, 23,
1137–1146.
(47) Gref, R.; et al. Biodegradable long-circulating polymeric nano-
spheres. Science 1994, 263, 1600–1603.
(48) Ben-Shabat, S.; Kumar, N.; Domb, A. J. PEG-PLA block
copolymer as potential drug carrier: Preparation and character-
ization. Macromol. Biosci. 2006, 6, 1019–1025.
(49) Bazile, D.; et al. Stealth Me.PEG-PLA nanoparticles avoid uptake
by the mononuclear phagocytes system. J. Pharm. Sci. 1995,
84, 493–498.
(50) Peracchia, M. T.; et al. Stealth PEGylated polycyanoacrylate
nanoparticles for intravenous administration and splenic targeting.
J. Controlled Release 1999, 60, 121–128.
(51) Peracchia, M. T.; et al. Visualization of in vitro protein-rejecting
properties of PEGylated stealth polycyanoacrylate nanoparticles.
Biomaterials 1999, 20, 1269–1275.
(52) Li, Y.; et al. PEGylated PLGA nanoparticles as protein carriers:
Synthesis, preparation and biodistribution in rats. J. Controlled
Release 2001, 71, 203–211.
(53) Gref, R.; et al. ‘Stealth’ corona-core nanoparticles surface
modiﬁed by polyethylene glycol (PEG): Inﬂuences of the corona
(PEG chain length and surface density) and of the core
composition on phagocytic uptake and plasma protein adsorption.
Colloids Surf. 2000, 18, 301–313.
(54) Scott, M. D.; Murad, K. L. Cellular camouﬂage: Fooling the
immune system with polymers. Curr. Pharm. Des. 1998, 4, 423–
438.
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VOL. 5, NO. 4 MOLECULAR PHARMACEUTICS 509Gref et al. were the ﬁrst to report the advantages of
pegylation on PLGA-PEG nanoparticles, resulting in a
substantial increase in blood residence time. Apolipoproteins
(A-IV and E) were found to be present on the surface of
pure PLA nanoparticles in contrast to the PLA-PEG
nanoparticles using gel electrophoresis analysis.
53 Although
the assay did not provide a precise quantitative analysis, it
was clearly shown that protein adsorption, particularly
apolipoprotein J and complement protein C3, was substan-
tially reduced on the surface of the PLA-PEG nanoparticles
compared with pure PLA formulations. These results suggest
that these speciﬁc apolipoproteins might also play a role in
the process of opsonization of the particles. Gref et al.
53 have
systematically studied the effect of PEG chain length in
preventing protein adsorption on the surface of the nano-
particles. The results showed that an optimal molecular mass
(Mw) range exists (between 2 and 5 kDa) in order to reduce
plasma protein adsorption. The amount of protein absorbed
on PLA-PEG 5 kDa was substantially reduced (∼80%)
compared to the amount of nonpegylated PLA nanoparticles.
PEG content as low as 0.5 wt % on the surface of the
nanoparticles was able to signiﬁcantly reduce the total
amount of protein when compared to the nonpegylated PLA
nanoparticles. The most signiﬁcant reduction of protein
absorption was found for pegylated particles (5 wt %). The
effect of PEG on the surface of the nanoparticle in preventing
protein absorption correlated with the polymorphonuclear
leukocyte (PMN) and human monocyte (THP-1) uptake.
Interestingly, a threshold of 1-2 nm space between the PEG
chains was estimated for minimal protein absorption. Since
then, many research groups have investigated the interaction
of polymeric nanoparticles with serum opsonins, character-
izing both uptake mechanisms and kinetics.
53,56–58 In one
study, the relationship between the protein adsorption kinetics
of the nanoparticles and their uptake in the liver was
investigated.
56 The results showed that the rate of hepatic
uptake of polystyrene nanoparticles (50 nm) was signiﬁcantly
higher when nanoparticles were incubated with serum prior
to transfusion in the rat liver. It was suggested that the
increased rate of hepatic uptake was mainly mediated by
opsonization. In vitro uptake studies showed that the
increased amount of complement protein C3 and immuno-
globulin G (IgG) adsorbed on nanoparticles was directly
reﬂected in the increased rate of uptake of nanoparticles by
Kupffer cells. These results indicate that the amount of
opsonins associated with the surface of the nanoparticles
increased over time and triggered substantial hepatic ag-
glomeration. Similarly, C. Fang et al.
59 have recently shown
the effect of the molecular mass of PEG for passive targeting
of stealth poly(cyanoacrylate-co-n-hexadecyl) cyanoacrylate
(PHDCA) nanoparticles. As in previous studies, PEG surface
modiﬁcation of nanoparticles was able to dramatically reduce
protein absorption as detected using quantitative assays (BCA
assay). The amount of protein adsorbed was directly de-
pendent on the molecular mass of the PEG. Medium-sized
pegylated nanoparticles (100-200 nm) showed 10-40%
protein absorption, and PEG 10 kDa was found to be the
most efﬁcient size of PEG as compared to PEG 2 kDa and
PEG 5 kDa in preventing protein absorption. The results
suggest that a dense PEG shielding over a negatively charged
surface is important in preventing protein absorption. The
trend in shielding properties was conﬁrmed by the analysis
of nanoparticle uptake by murine macrophages and blood
clearance kinetics. Interestingly, the level of tumor necrosis
factor-R (TNF-R) delivered by nanoparticles into tumor-
bearing mice was clearly correlated with the shielding
density. Another recent example conﬁrmed the advantages
of surface pegylation by utilizing thiolated gelatin nanopar-
ticles (∼300 nm) to improve passive tumor targeting in an
orthotopic human breast adenocarcinoma xenograft mouse
model.
60 Despite the fact that these particles were twice the
size of those in the previous study, the results showed a lower
rate of uptake of the PEG-modiﬁed nanoparticles by the liver,
indicative of the stealth properties of pegylated nanoparticles.
In general, pegylated nanoparticles were found to have longer
circulation time and higher levels of tumor accumulation than
nonpegylated nanoparticles. In summary, much has been
learned about PEG molecular mass and PEG density on
nanoparticles which has led to reduced plasma protein
adsorption, opsonization, and nonspeciﬁc uptake. In turn, this
has resulted in increased nanoparticle circulation half-life and
improved therapeutic efﬁcacy of drugs delivered using
pegylated nanocarriers.
Effect of Size. On the basis of physiological parameters
such as hepatic ﬁltration, tissue extravasation, tissue diffu-
sion, and kidney excretion, it is clear that, along with surface
composition, particle size is a key factor in the biodistribution
of long-circulating nanoparticles and achieving therapeutic
efﬁcacy (Figure 2). In one study, in vivo biodistribution
results of polystyrene nanoparticles with consistent composi- (55) Francis, G. E.; Delgado, C.; Fisher, D.; Malik, F.; Agrawal, A. K.
Polyethylene glycol modiﬁcation: Relevance of improved meth-
odology to tumour targeting. J. Drug Targeting 1996, 3, 321–
340.
(56) Nagayama, S.; Ogawara, K.; Fukuoka, Y.; Higaki, K.; Kimura,
T. Time-dependent changes in opsonin amount associated on
nanoparticles alter their hepatic uptake characteristics. Int.
J. Pharm. 2007, 342, 215–221.
(57) Panagi, Z.; et al. Effect of dose on the biodistribution and
pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int.
J. Pharm. 2001, 221, 143–152.
(58) Beletsi, A.; Panagi, Z.; Avgoustakis, K. Biodistribution properties
of nanoparticles based on mixtures of PLGA with PLGA-PEG
diblock copolymers. Int. J. Pharm. 2005, 298, 233–241.
(59) Fang, C.; et al. In vivo tumor targeting of tumor necrosis factor-
R-loaded stealth nanoparticles: Effect of MePEG molecular
weight and particle size. Eur. J. Pharm. Sci. 2006, 27, 27–36.
(60) Kommareddy, S.; Amiji, M. Biodistribution and pharmacokinetic
analysis of long-circulating thiolated gelatin nanoparticles fol-
lowing systemic administration in breast cancer-bearing mice.
J. Pharm. Sci. 2007, 96, 397–407.
(81) Rijcken, C. J.; Snel, C. J.; Schiffelers, R. M.; van Nostrum, C. F.;
Hennink, W. E. Hydrolysable core-crosslinked thermosensitive
polymeric micelles: Synthesis, characterisation and in vivo
studies. Biomaterials 2007, 28, 5581–5593.
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510 MOLECULAR PHARMACEUTICS VOL. 5, NO. 4tion and varying particle sizes of 50 and 500 nm showed
higher levels of agglomeration of the larger nanoparticles in
the liver.
56 It was suggested that the mechanism of hepatic
uptake was mediated by surface absorption of proteins
leading to opsonization. However, the effect of temperature
(37 °Cv s4°C) on hepatic elimination showed unexpectedly
faster uptake of the 50 nm polystyrene nanoparticles at the
lower temperature. Similarly, the size of the nanoparticle was
shown to have a substantial effect on the protein absorption.
Small (<100 nm), medium (100-200 nm), and large (>200
nm) pegylated PHDCA nanoparticles incubated with serum
protein for 2 h showed a signiﬁcant correlation between
particle size and protein absorption.
59Protein absorption on
small nanoparticles (80 nm) was quantiﬁed (6%) and
compared to the same nanoparticle formulation with a larger
size (171 and 243 nm, 23 and 34%, respectively). The effect
of protein absorption on different sized nanoparticles was
also conﬁrmed with the analysis of nanoparticle uptake by
murine macrophages and blood clearance kinetics. Blood
clearance of the smaller nanoparticles was twice as slow as
with the larger nanoparticle formulations. More importantly,
the amount of drug encapsulated (TNF-R) in nanoparticles
that accumulated in the tumor within 24 h was twice that of
the larger nanoparticle formulation. The results suggest that
it might be due to a higher surface PEG density (brushlike)
on the surface of smaller nanoparticles. Rijcken et al.
81 have
shown that size and polydispersity can substantially affect
the biodistribution of micelles. Cross-linked micelles incu-
bated in PBS (pH 7.4) at 37 °C for more than 3 days did not
show substantial increases in size and polydispersity in
contrast to non-cross-linked micelles (PD ∼ 0.5 after 10 h).
Stable micelles showed a long circulation half-life of ∼8h
due to a low rate of hepatic uptake (liver ∼ 10% of the
injected dose; spleen ∼ 2% of the injected dose). Similar to
results with small liposomes (<100 nm), micelles were found
to accumulate in the skin.
In summary, it has been consistently shown that pegylated
nanoparticles smaller than 100 nm have reduced plasma
protein adsorption on their surface and also have reduced
hepatic ﬁltration. Further, these small pegylated nanoparticles
have a long blood residence time and a high rate of
extravasation into permeable tissues, demonstrating the
importance of tunable particle size and surface composition
for achieving effective, targeted delivery.
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Cancer 2004, 91, 1775–1781.
(80) Hopewel, J. W.; Duncan, R.; Wilding, D.; Chakrabarti, K.
Preclinical evaluation of the cardiotoxicity of PK2: A novel
HPMA copolymer-doxorubicin-galactosamine conjugate antitu-
mour agent. Hum. Exp. Toxicol. 2001, 20, 461–470.
(82) Shenoy, D.; Little, S.; Langer, R.; Amiji, M. Poly(ethylene
oxide)-modiﬁed poly( -amino ester) nanoparticles as a pH-
sensitive system for tumor-targeted delivery of hydrophobic
drugs: Part 2. In vivo distribution and tumor localization studies.
Pharm. Res. 2005, 22, 2107–2114.
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82 investigated the
biodistribution of stealth poly( -amino ester) nanoparticles
(PbAE) and poly(caprolactone) (PCL)-based nanoparticles
with a similar size range of 100-200 nm. In addition, both
nanoparticle formulations had a very high positive surface
charge of approximately +30 mV. The results clearly showed
a signiﬁcantly higher level of accumulation in the heart
and lung tissues for the PbAE nanoparticles. This was
correlated with a lower level of accumulation in the liver as
compared to PCL nanoparticles. It was suggested that a
higher degree of aggregation of PbAE nanoparticles in the
presence of serum proteins affected the biodistribution
leading, to such high levels of accumulation in the lung.
Recently, greater degrees of nanoparticle “ﬂexibility” were
hypothesized to improve the binding ability of particles on
the cell surface.
83 Shell cross-linked nanoparticles (SCKs)
containing partially hydrochlorinated poly(isoprene) cores
were shown to undergo temperature-dependent deforma-
tion.
84 SCK nanoparticles with similar physiochemical
properties (size, ca. 20 nm;  , ca. -25 mV) possessing a
low glass transition temperature (Tg) with a ﬂuidlike poly-
(methyl acrylate) (PMA) core or a high Tg with a glassy
poly(styrene) (PS) core were synthesized to evaluate the
effects of the rigidity of the polymeric core on the in vivo
biodistribution.
84 The results showed that high-Tg poly(sty-
rene) core nanoparticles exhibited a signiﬁcantly higher blood
residence time compared to the low-Tg poly(methyl acrylate)
nanoparticles. The low-Tg core is expected to provide greater
ﬂexibility and an increased number of surface interactions
of the nanoparticles with the tissues and biological environ-
ment. However, it was not clear if the relative rigidity or
other physicochemical properties of the polymers (hydro-
phobicity) affected the blood residence time. The results
suggested that the composition of the core has an important
effect on the blood residence time. In this case, PEG surface
modiﬁcations did not have a noticeable effect on kidney
accumulation and clearance most probably due to the small
size of the nanoparticle formulations. These results are
consistent with previous work investigating the effect of the
core composition on the nature of absorbed proteins using a
series of block copolymers with the same PEG thickness and
density.
85 Copolymers of poly(ethylene glycol) (PEG) and
polyesters with increased hydrophobicity (PLGA, PLA, and
PCL) were synthesized.
85 Evidence of C3 cleavage was used
as a semiquantitative way to characterize the level of
complement activation by naked and pegylated nanocapsules
(NCs) formed with different core copolymers. The results
showed that PLA NCs prepared from biodegradable poly-
esters act as strong activators of complement. Since PCL
showed a lower level of complement activation, the reason
for the stronger complement response did not seem to
correlate with the hydrophobicity of the copolymer. However,
pegylated NCs had signiﬁcantly reduced levels of comple-
ment activation which were shown to depend on PEG chain
length and density. In another study, polymeric nanoparticles
coated with polysorbate were shown to be able to accumulate
in the brain tissues.
86 The brain blood vessels are character-
ized by tight junctions between endothelial cells possessing
a TEER (trans-endothelial electrical resistance) of ap-
proximately 1500-2000 Ω/cm
2 which prevents paracellular
transport of molecules and represents a biological barrier for
delivery of the drug to the brain. However, poly(butyl
cyanoacrylate) nanoparticles coated with polysorbate 80 were
able to deliver signiﬁcant amounts of doxorubicin to the
brain. Multiple formulations were studied, and polysorbate
80-coated nanoparticles exhibited a high doxorubicin con-
centration (6 µg/g) in brain tissues as compared to noncoated
nanoparticles (0.1 µg/g). It was found that apolipoprotein E
(apoE) binds substantially to polysorbate 80 surfactants, and
the results suggest that apoE is involved in the mediated
transport of the polysorbate 80-coated nanoparticles to the
brain. Further explanation of the high concentration of
doxorubicin drug delivered to the brain can be derived from
the fact that polysorbate can act as an anchor for apoE protein
binding and interact with LDL receptors expressed in the
brain blood vessels. Polysorbate 80 also has been shown to
have Pgp inhibition properties which could provide an
additional rationale for the delivery of the doxorubicin with
nanoparticles having a polysorbate 80 coating.
87 Recently,
Shaw and Weissleder (in press in Proceedings of the National
Academy of Sciences of the United States of America) have
found interesting results regarding the core composition and
relative toxicities of nanoparticles utilizing an in vitro, high-
throughput, multidimensional analysis across varying con-
centrations utilizing multiple cell types and multiple assays
of cellular physiology. Their generalizable, systematic ap-
proach indicates that biological effects result from the
combined effects of many aspects of nanoparticle composi-
tion, including the core composition which was found to have
a somewhat surprising effect on biological properties. Future
work developing such structure-activity relationships may
shed even more light on the complex interplay between
nanoparticle properties and subsequent biological effects. In
summary, it has been found that physicochemical properties
of the core are critical parameters of the nanoparticle
formulations. Precise modiﬁcations of these properties are
able to dramatically affect the extent of interactions with
blood and biodistribution of nanoparticles.
(83) Takeoka, S.; et al. Rolling properties of rGPIbR-conjugated
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in vivo biodistribution. Biomacromolecules 2005, 6, 2541–2554.
(85) Mosqueira, V. C.; et al. Relationship between complement
activation, cellular uptake and surface physicochemical aspects
of novel PEG-modiﬁed nanocapsules. Biomaterials 2001, 22,
2967–2979.
(86) Gulyaev, A. E.; et al. Signiﬁcant transport of doxorubicin into
the brain with polysorbate 80-coated nanoparticles. Pharm. Res.
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established that the physicochemical characteristics of a
polymeric nanoparticle such as surface charge and functional
groups can affect its uptake by the cells of the phagocytic
system. It was previously shown that polystyrene micropar-
ticles with a primary amine at the surface underwent
signiﬁcantly more phagocytosis as compared to micropar-
ticles having sulfate, hydroxyl, and carboxyl groups. There-
fore, it is well accepted that positively charged nanoparticles
have a higher rate of cell uptake compared to neutral or
negatively charged formulations. Nanoparticles carrying a
positively charged surface are also expected to have a high
nonspeciﬁc internalization rate and short blood circulation
half-life. Nanoshells having a negative surface charge have
shown a marked reduction in the rate of uptake. The  
potential for nanoshells with BSA absorbed on the surface
of the nanoparticle was characterized by a shift to a more
negative value. However, the BSA absorption did not
promote a higher rate of cell uptake. Interestingly, when the
biodistribution of Tyr- and Tyr-Glu-PEG/PDLLA micelles
was investigated in mice,
88 both the Tyr- (neutral) and Tyr-
Glu (negatively charged) PEG/PDLLA micelles exhibited
no remarkable difference in their blood clearance kinetics.
The pharmacokinetic parameters suggest that all the micelle
formulations are distributed mainly into the extracellular
space volume of the spleen and liver. However, the anionic
Tyr-Glu-PEG/PDLLA micelles showed a lower distribution
(10 times lower) into the liver and spleen 4 h post-injection.
Remarkably, a lower level of accumulation of Tyr-Glu-PEG/
PDLLA micelles into the liver and spleen is believed to be
due to synergic steric and electrostatic repulsion which
decrease the rate of cellular uptake. In addition, urinary
excretion was the major excretion route, conﬁrming a low
rate of hepatic uptake of the micelle formulation. Recently,
thiolated gel nanoparticles (∼250 nm; ca. -5 mV)
60 have
had a higher level of tumor accumulation than nonthiolated
nanoparticles, and it was correlated with a very short plasma
half-life of ∼3 h, indicating a possible preferential uptake
or accumulation in the tumor tissues. In addition, the thiolated
nanoparticles were found to have a higher rate of uptake
into the spleen. The reasons for such an impact of the
thiolated functional group on the surface of the nanoparticles
are not very clear, but it could be due to aggregation of
nanoparticles through disulﬁde bond formation or reaction
with thiolated molecules circulating in the blood. In sum-
mary, it is established that neutral or negatively charged
surface nanoparticles have a reduced plasma protein adsorp-
tion and low rate of nonspeciﬁc cellular uptake. Thus, surface
functionality is another critical parameter in controlling the
development of long-circulating nanoparticles.
Effect of Active Targeting. Active targeting of nanopar-
ticles involves the conjugation of targeting ligands to the
surface of nanoparticles. These ligands can include antibod-
ies, engineered antibody fragments, proteins, peptides, small
molecules, and aptamers. The active targeting mechanism
takes advantage of highly speciﬁc interactions between the
targeting ligand and certain tissues or cells within the body
to promote the accumulation of nanoparticles.
3,89–92 In the
case of weak binding ligands, low afﬁnity can be offset by
increased avidity through the surface functionalization of
multiple molecules or multivalent designs and has been
shown to be a valid approach. There are several examples
of FDA-approved antibodies in clinical practice today,
93,94
including Rituxan (target, CD20-positive B-cells for the
treatment of non-Hodgkin’s lymphoma and rheumatoid
arthritis), Herceptin (target, HER-2-overexpressing breast
cancer cells), Erbitux [target, epidermal growth factor
receptor (EGFR) for the treatment of colorectal cancer],
Iressa (target, EGFR for the treatment of non-small cell lung
cancer and metastatic breast cancer), and Avastin [target,
vascular epidermal growth factor (VEGF) for the treatment
of metastatic colorectal, non-small lung, and breast cancers].
While the progress with monoclocal antibodies has been
encouraging, they have not been shown to be curative. This
has led to the development of immunoconjugates with the
intent of utilizing the targeting speciﬁcity of the antibody to
deliver a relatively potent drug. The development of immu-
noconjugates has been slow due to various challenges but
has resulted in the FDA approval of three immunoconju-
gates
46 such as Mylotarg (conjugate of calicheamicin target-
ing CD33 for the treatment of acute myeloid leukemia),
Zevalin (yttrium-90 radio-immunotherapy conjugates target-
ing CD20-positive B-cells for the treatment of non-Hodgkin’s
lymphoma), and tositumomab (
131I radio-immunotherapy
conjugates targeting CD20-positive B-cells for the treatment
of non-Hodgkin’s lymphoma). Currently, drug delivery
carriers are being functionalized with proteins, including
antibodies or antibody fragments and various other targeting
ligands, with the goal of both delivering a high therapeutic
dose and delivering this high therapeutic dose to speciﬁc
tissues or cells. Conjugation approaches for controlling the
amount of targeting proteins on the surface of the nanopar-
ticles have been developed to increase speciﬁcity and binding
afﬁnity. Research using proteins for targeting applications
has led to a better understanding of the effect of stability
and size of the ligand for successful targeting and clinical
(88) Yamamoto, Y.; Nagasaki, Y.; Kato, Y.; Sugiyama, Y.; Kataoka,
K. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block
copolymer micelles with modulated surface charge. J. Controlled
Release 2001, 77, 27–38.
(89) Freeman, A. I.; Mayhew, E. Targeted drug delivery. Cancer 1986,
58, 573–583.
(90) Emerich, D. F.; Thanos, C. G. Targeted nanoparticle-based drug
delivery and diagnosis. J. Drug Targeting 2007, 15, 163–183.
(91) van Vlerken, L. E.; Vyas, T. K.; Amiji, M. M. Poly(ethylene
glycol)-modiﬁed nanocarriers for tumor-targeted and intracellular
delivery. Pharm. Res. 2007, 24, 1405–1414.
(92) Peppas, N. A. Intelligent therapeutics: Biomimetic systems and
nanotechnology in drug delivery. AdV. Drug DeliVery ReV. 2004,
56, 1529–1531.
(93) Schrama, D.; Reisfeld, R. A.; Becker, J. C. Antibody targeted
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5, 147–159.
(94) Weiner, L. M.; Adams, G. P. New approaches to antibody
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95,96 Antibody molecules are very large and
complex and can be expensive to manufacture relative to
small-molecule drugs. In addition, antibodies have a hydro-
dynamic size of ∼20 nm that can increase the size of the
NPs. Recently, Davis et al.
97 have demonstrated the thera-
peutic impact of differential distribution between intracellular
and extracellular tumor domains. Cyclodextran-based nano-
particles containing transferrin targeting ligand (NP size of
∼70 nm) showed enhanced intracellular accumulation in a
human tumor xenograft mouse model. Interestingly, the
model of tumor accumulation and uptake ﬁt the experimental
data, suggesting that tumor retention time and internalization
into tumor cells are the critical factors affecting accumulation
of nanoparticles in targeted tissues. The same group
98
reported the ﬁrst toxicology study of a targeted, polymeric
nanoparticle platform in non-human primates as reported
above. This type of study is crucial for answering the
numerous critical questions about the toxicological response
to polymeric nanoparticles circulating in the blood. The
results clearly show that their intravenously injected poly-
meric nanoparticles were safely administered to non-human
primates even after multiple administrations over 3 weeks.
These promising results led to the submission of an
investigational new drug application.
While targeting with proteins has been shown to be
advantageous in some cases, for various reasons, it may be
desirable to achieve targeting with relatively small targeting
ligands that are potentially easier to manufacture. The
discovery of new peptide targeting domains
99 provides the
advantage of being able to utilize small synthetic molecules
for active targeting. One such example is peptides which
are relatively stable compared to antibodies and are also less
likely to be immunogenic. Similarly, small molecules can
be very attractive for use as targeting ligands, and small
molecules such as folic acid or sugar molecules have been
extensively used. For example, cell surface membrane lectins
have been shown to be overexpressed on the surface of
numerous cancer cells and are able to speciﬁcally internalize
sugar molecules (lactose, galactose, and mannose).
5 Simi-
larly, nucleic acid aptamers are able to fold into unique
structures capable of binding to speciﬁc targets with high
afﬁnity and speciﬁcity.
100 Favorable characteristics of aptam-
ers have resulted in their rapid progress into clinical
applications. Our group is interested in developing this class
of molecules for targeted delivery of controlled drug-
releasing polymer vehicles.
101 We described the ﬁrst proof-
of-concept drug delivery polymeric nanoparticle utilizing
aptamers as targeting ligands in vitro
102 and subsequently
showed the efﬁcacy of similarly designed nanoparticles
against prostate cancer tumors in vivo.
103 In vivo results
using a human prostate cancer tumor xenograft mouse model
showed a signiﬁcant therapeutic efﬁcacy of aptamer-targeted
nanoparticles loaded with docetaxel compared to nontargeted
formulations. Targeted nanoparticles substantially reduced
the size of the tumor after a single intratumoral injection,
and all of the treated mice survived more than 3 months in
contrast to other controls. More recently, we reported a novel
strategy for facile synthesis of targeted nanoparticle formula-
tions.
104 We have shown that targeted nanoparticles specif-
ically accumulated in the prostate tumor xenograft mouse
model (∼1.8%ID/g of tissue) compared to nontargeted
nanoparticles (0.5%ID/g of tissue). In summary, it has now
been shown both in vitro and in vivo that targeted nanopar-
ticles are able to agglomerate in speciﬁc tissues to improve
the therapeutic efﬁcacy, and there is a growing body of
literature in this area. Clearly, active targeting provides a
powerful approach to increasing the drug delivery load at a
speciﬁc site for treatment.
Conclusion
The exact role of each of the proteins adsorbed on the
surface of the nanoparticles in the clearance and biodistri-
bution is still not clear besides their role in opsonization and
enhanced hepatic uptake. It is generally assumed that the
rapid uptake of injected nanoparticles is triggered by recep-
tor-mediated mechanisms of absorbed proteins from the
blood (opsonins) onto their surface and complement activa-
tion. However, it is not clear if a speciﬁc type, a combination
of proteins, or even the protein conformation is the most
important factor for a high rate of phagocytotic uptake. The
efﬁcacy of the PEG “brush” in altering the biodistribution
of nanoparticles has been clearly demonstrated, and in vivo
studies showed a drastic increase in blood circulation time
(95) Clauss, M. A.; Jain, R. K. Interstitial transport of rabbit and sheep
antibodies in normal and neoplastic tissues. Cancer Res. 1990,
50, 3487–3492.
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(97) Bartlett, D. W.; Su, H.; Hildebrandt, I. J.; Weber, W. A.; Davis,
M. E. Impact of tumor-speciﬁc targeting on the biodistribution
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in vivo imaging. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 15549–
15554.
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ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad.
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2004, 64, 7668–7672.
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514 MOLECULAR PHARMACEUTICS VOL. 5, NO. 4with an increase in PEG surface density. It is also clear that
relatively small physicochemical differences have signiﬁcant
biological implications in the fate of the biodistribution of
nanoparticles. Pegylated nanoparticles between 10 and 100
nm in size are able to remain in the systemic circulation for
hours and extravasate or diffuse into the diseased tissues by
a passive targeting mechanism. Recently, targeted nanopar-
ticles funtionalized with ligands that have high afﬁnity and
speciﬁcity have been shown to efﬁciently accumulate in
speciﬁc tissues and dramatically increase the therapeutic
efﬁcacy of long-circulating nanoparticle drug delivery sys-
tems. Natural and synthetic polymers are now in preclinical
and clinical phases for drug delivery. More importantly,
targeted and nontargeted polymeric nanoparticles are now
in the preclinical and clinical phases and conﬁrm the great
promise of the past 20 years of research and lessons learned
from the failure of some clinical studies to increase the
therapeutic index of drugs approved for clinical use.
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